Voyager V1 - Vyriad

Drug Profile

Voyager V1 - Vyriad

Alternative Names: VSV-IFNβ-NIS; VSV-IFNβ-NIS - Vyriad

Latest Information Update: 04 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vyriad
  • Developer Mayo Clinic; National Cancer Institute (USA); Vyriad
  • Class Cancer vaccines; Gene therapies; Interferons; Oncolytic viruses
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; Interferon-beta-replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Solid tumours
  • Phase I Acute myeloid leukaemia; Endometrial cancer; Multiple myeloma; T cell lymphoma

Most Recent Events

  • 04 Sep 2018 VSV IFNbeta NIS - Vyriad is available for licensing as of 04 Sep 2018.
  • 27 Aug 2018 Vyriad plans a phase I trial for Non-Small Cell Lung Cancer and Hepatocellular Carcinoma (Combination therapy; Refractory metastatic disease; Second-line therapy or greater) in USA , (NCT03647163)
  • 18 Jul 2018 Vyriad enter into a collaboration agreement with Merck and Pfizer for the development of VSV-IFNβ-NIS in combination with avelumab for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top